▁Introduction 7.82421875
: 1.9072265625
<0x0A> 6.53125
In 3.4140625
▁the 1.5205078125
▁rel 10.21875
ent 0.360595703125
less 0.026824951171875
▁fight 4.6328125
▁against 0.6611328125
▁cancer 3.23828125
, 0.1605224609375
▁British 10.125
▁Bi 6.48046875
ote 0.173095703125
ch 0.12451171875
▁Pl 6.1953125
c 0.007965087890625
' 4.3984375
s 0.0009694099426269531
▁experimental 6.4921875
▁drug 1.1259765625
, 1.51953125
▁Mar 6.89453125
im 2.70703125
ast 0.008697509765625
at 5.6624412536621094e-05
, 0.285400390625
▁has 1.2392578125
▁emer 2.25
ged 0.0004730224609375
▁as 0.138671875
▁a 0.62353515625
▁prom 2.56640625
ising 0.0014982223510742188
▁candidate 2.732421875
▁for 1.359375
▁potentially 6.84765625
▁revolution 3.974609375
izing 0.7177734375
▁cancer 1.8837890625
▁treatment 0.388916015625
. 0.25390625
▁Early 8.265625
▁results 1.8896484375
▁and 5.6484375
▁encourag 4.24609375
ing 0.0159759521484375
▁data 2.166015625
▁have 1.6630859375
▁raised 3.33203125
▁hopes 0.9609375
▁for 1.2822265625
▁an 3.66796875
▁effective 0.6875
▁ther 3.494140625
apy 0.0006833076477050781
, 2.513671875
▁but 1.4140625
▁the 1.7060546875
▁drug 2.2890625
▁still 2.134765625
▁faces 0.384521484375
▁significant 1.4453125
▁obst 2.46875
acles 0.00022971630096435547
▁before 1.0146484375
▁it 0.2210693359375
▁can 0.126708984375
▁achieve 4.42578125
▁block 8.0625
b 0.001949310302734375
uster 0.0009522438049316406
▁status 0.212646484375
. 0.1982421875
▁As 4.46875
▁the 1.1962890625
▁bi 3.748046875
ote 0.08404541015625
ch 0.297607421875
▁industry 0.50537109375
▁eager 6.546875
ly 6.711483001708984e-05
▁a 0.1707763671875
wa 3.3855438232421875e-05
its 1.2993812561035156e-05
▁further 2.232421875
▁adv 3.970703125
anc 0.87646484375
ements 0.0005245208740234375
, 1.1650390625
▁the 1.69921875
▁road 4.640625
▁ahead 0.73876953125
▁for 1.412109375
▁Mar 0.1329345703125
im 0.002239227294921875
ast 0.00037860870361328125
at 0.0002472400665283203
▁remains 0.5908203125
▁uncertain 0.93017578125
▁due 6.53125
▁to 0.00763702392578125
▁regul 2.271484375
atory 0.0018215179443359375
▁challeng 2.349609375
es 5.412101745605469e-05
, 0.7841796875
▁inten 5.28515625
se 0.00014901161193847656
▁competition 0.038299560546875
, 0.76123046875
▁and 0.1572265625
▁potential 2.90234375
▁financial 4.65625
▁hur 1.7568359375
d 1.7404556274414062e-05
les 4.088878631591797e-05
. 0.03387451171875
<0x0A> 0.76171875
Reg 2.62109375
ul 0.026641845703125
atory 0.0012416839599609375
▁Ch 0.6376953125
alleng 0.0012836456298828125
es 0.00011324882507324219
: 0.10894775390625
<0x0A> 0.329833984375
Des 3.142578125
p 0.0030498504638671875
ite 0.00016748905181884766
▁demonstr 5.5
ating 0.0030422210693359375
▁promise 4.1953125
, 2.638671875
▁Mar 0.21875
im 0.00104522705078125
ast 0.0002162456512451172
at 0.0015106201171875
▁must 3.431640625
▁navigate 2.814453125
▁a 1.1875
▁complex 0.68359375
▁and 2.44921875
▁rig 2.43359375
orous 0.01470947265625
▁regul 0.267578125
atory 1.1086463928222656e-05
▁process 0.71337890625
▁before 0.39208984375
▁reaching 3.08203125
▁the 0.265380859375
▁market 0.0975341796875
. 0.037506103515625
▁The 0.69384765625
▁drug 0.580078125
' 1.7978515625
s 8.618831634521484e-05
▁effic 3.15625
acy 2.6106834411621094e-05
▁and 0.4287109375
▁safety 0.023162841796875
▁profile 2.30859375
▁will 1.333984375
▁be 0.289306640625
▁crit 5.72265625
ically 0.01091766357421875
▁review 3.806640625
ed 4.2319297790527344e-05
▁by 0.097412109375
▁regul 0.7470703125
atory 0.30908203125
▁authorities 0.9296875
▁such 2.154296875
▁as 0.0001741647720336914
▁the 0.007396697998046875
▁U 1.7158203125
. 0.0004220008850097656
S 0.00910186767578125
. 0.016632080078125
▁Food 0.03460693359375
▁and 0.018218994140625
▁D 0.00012922286987304688
rug 2.384185791015625e-07
▁Administration 0.00047206878662109375
▁( 0.06500244140625
F 0.0003647804260253906
DA 0.0001742839813232422
) 0.26416015625
▁and 0.1243896484375
▁the 0.58349609375
▁European 0.0233917236328125
▁Medic 0.01403045654296875
ines 9.763240814208984e-05
▁Agency 0.002574920654296875
▁( 0.011474609375
EMA 0.0003383159637451172
). 0.392333984375
▁Given 5.20703125
▁the 0.2156982421875
▁string 3.833984375
ent 0.02099609375
▁requirements 0.7880859375
▁and 1.822265625
▁extensive 3.23046875
▁testing 1.7529296875
▁phases 8.5546875
▁involved 1.5751953125
, 0.53857421875
▁British 8.2265625
▁Bi 0.0021343231201171875
ote 0.000125885009765625
ch 0.0005369186401367188
▁Pl 0.869140625
c 0.00011610984802246094
▁must 1.912109375
▁address 4.64453125
▁any 1.2275390625
▁potential 1.6953125
▁concerns 1.087890625
▁or 1.435546875
▁side 5.1484375
▁effects 0.01415252685546875
▁to 1.7685546875
▁ensure 1.2255859375
▁Mar 2.798828125
im 0.0007333755493164062
ast 7.343292236328125e-05
at 0.0010356903076171875
' 0.9404296875
s 0.0001125335693359375
▁successful 4.0625
▁journey 5.703125
▁through 0.86572265625
▁regul 2.3046875
atory 0.0003638267517089844
▁appro 0.310791015625
val 8.58306884765625e-06
. 0.23388671875
<0x0A> 0.1124267578125
Int 0.830078125
ense 0.00482177734375
▁Compet 0.059814453125
ition 0.00179290771484375
▁and 5.55859375
▁Market 3.091796875
▁Land 4.703125
s 0.0003573894500732422
cape 0.0003075599670410156
: 0.023468017578125
<0x0A> 0.007205963134765625
Mar 1.9873046875
im 0.0005736351013183594
ast 6.115436553955078e-05
at 0.00010383129119873047
▁enters 6.67578125
▁a 0.1920166015625
▁fier 4.28515625
c 0.10369873046875
ely 0.00018346309661865234
▁compet 0.0209197998046875
itive 1.4066696166992188e-05
▁market 0.65087890625
, 1.1123046875
▁challeng 5.16015625
ing 1.443359375
▁established 3.203125
▁players 1.1376953125
▁who 3.9453125
▁have 0.44140625
▁already 1.123046875
▁made 2.333984375
▁significant 0.548828125
▁str 2.111328125
ides 1.3113021850585938e-06
▁in 0.07611083984375
▁cancer 1.3056640625
▁treatment 0.3642578125
. 0.0518798828125
▁R 6.2890625
ival 0.265380859375
▁ph 3.029296875
arma 0.005237579345703125
ce 0.035125732421875
ut 2.0265579223632812e-06
ical 2.8133392333984375e-05
▁companies 0.324951171875
▁have 1.8720703125
▁inv 1.8095703125
ested 1.919269561767578e-05
▁heavily 0.7021484375
▁in 0.01264190673828125
▁developing 1.1611328125
▁cutting 5.91015625
- 0.0007524490356445312
edge 7.212162017822266e-05
▁ther 0.6923828125
ap 0.00031280517578125
ies 3.0994415283203125e-06
, 0.564453125
▁some 5.00390625
▁of 0.2332763671875
▁which 0.002399444580078125
▁have 0.7099609375
▁gained 3.8515625
▁regul 1.3818359375
atory 4.744529724121094e-05
▁appro 0.00222015380859375
val 1.430511474609375e-06
▁and 0.56591796875
▁achieved 3.669921875
▁impress 3.677734375
ive 1.823902130126953e-05
▁clin 4.4375
ical 6.0439109802246094e-05
▁out 1.54296875
comes 5.841255187988281e-06
. 0.02203369140625
▁British 2.369140625
▁Bi 0.0022144317626953125
ote 9.059906005859375e-06
ch 0.00015914440155029297
▁Pl 0.0194244384765625
c 8.463859558105469e-05
▁must 0.7216796875
▁find 4.21484375
▁its 3.7109375
▁place 1.89453125
▁within 2.294921875
▁this 0.1517333984375
▁crow 0.92236328125
ded 2.4437904357910156e-05
▁landscape 0.55078125
▁by 2.787109375
▁demonstr 1.4150390625
ating 6.318092346191406e-06
▁a 2.888671875
▁unique 1.3076171875
▁value 1.515625
▁proposition 0.0007829666137695312
▁and 0.7744140625
▁differenti 1.279296875
ating 0.1607666015625
▁Mar 1.28515625
im 0.0005373954772949219
ast 9.655952453613281e-05
at 6.61611557006836e-05
▁from 0.08514404296875
▁existing 1.6357421875
▁treatment 4.13671875
▁options 0.00920867919921875
. 0.019195556640625
<0x0A> 0.10113525390625
Fin 0.2978515625
an 0.032196044921875
cial 0.00014126300811767578
▁Con 5.25390625
stra 0.005802154541015625
ints 0.00093841552734375
▁and 0.322021484375
▁Market 3.462890625
▁Access 1.8193359375
: 0.213134765625
<0x0A> 0.0019683837890625
Develop 3.13671875
ing 0.03924560546875
▁and 0.52294921875
▁launch 2.97265625
ing 1.4424324035644531e-05
▁a 0.225830078125
▁ground 4.875
bre 0.1580810546875
aking 3.4570693969726562e-06
▁cancer 1.0498046875
▁drug 0.99853515625
▁is 1.091796875
▁an 0.9794921875
▁expensive 0.098388671875
▁ende 0.77685546875
avor 3.159046173095703e-05
, 0.18359375
▁requiring 1.4248046875
▁substantial 1.5263671875
▁financial 2.599609375
▁resources 0.84326171875
. 1.4833984375
▁British 0.50146484375
▁Bi 0.0010318756103515625
ote 5.841255187988281e-06
ch 4.6372413635253906e-05
▁Pl 0.004779815673828125
c 6.449222564697266e-05
▁may 2.833984375
▁face 0.5048828125
▁hur 2.837890625
d 2.384185791015625e-07
les 3.7550926208496094e-05
▁in 0.18115234375
▁se 0.619140625
cur 1.5497207641601562e-06
ing 5.245208740234375e-06
▁the 2.3125
▁fund 1.7998046875
ing 2.1576881408691406e-05
▁necessary 0.90966796875
▁for 2.060546875
▁the 2.970703125
▁drug 1.380859375
' 0.01454925537109375
s 3.552436828613281e-05
▁clin 1.431640625
ical 4.1604042053222656e-05
▁tri 0.452880859375
als 2.1457672119140625e-06
, 0.92236328125
▁manufact 0.810546875
uring 0.0023899078369140625
, 0.1690673828125
▁and 0.13232421875
▁market 0.908203125
ing 0.1341552734375
▁activities 4.6640625
. 0.05670166015625
▁Additionally 1.525390625
, 2.205371856689453e-05
▁questions 7.41015625
▁regarding 3.02734375
▁re 1.763671875
imb 0.0006976127624511719
urs 4.5418739318847656e-05
ement 0.00594329833984375
▁and 0.35595703125
▁market 1.9580078125
▁access 0.018646240234375
▁also 7.25390625
▁pose 2.48828125
▁challeng 2.34375
es 0.0006656646728515625
. 2.6796875
▁Dem 8.25
on 0.08740234375
str 0.00018143653869628906
ating 0.0040130615234375
▁the 0.8154296875
▁cost 3.103515625
- 0.0189971923828125
effect 0.01203155517578125
iveness 0.00582122802734375
▁and 0.74169921875
▁real 6.59375
- 0.01554107666015625
world 0.00911712646484375
▁benefits 1.228515625
▁of 0.01413726806640625
▁Mar 0.055572509765625
im 0.0002894401550292969
ast 9.894371032714844e-05
at 3.7670135498046875e-05
▁will 0.70703125
▁be 0.07684326171875
▁critical 1.0947265625
▁to 1.080078125
▁se 2.736328125
cur 4.649162292480469e-05
ing 3.2186508178710938e-06
▁ins 5.7890625
urance 0.07220458984375
▁coverage 0.1378173828125
▁and 0.12408447265625
▁a 5.0390625
▁fair 4.7265625
▁pr 2.740234375
icing 0.00014591217041015625
▁structure 0.5556640625
, 2.22265625
▁a 4.8515625
▁factor 5.23046875
▁that 0.07745361328125
▁can 2.091796875
▁greatly 3.748046875
▁influence 1.1953125
▁its 1.2421875
▁block 10.5546875
b 0.00021600723266601562
uster 0.00019741058349609375
▁potential 0.311767578125
. 0.02032470703125
<0x0A> 0.0188446044921875
C 4.01953125
lin 0.1695556640625
ical 0.0014486312866210938
▁Tri 0.6015625
als 0.7578125
▁and 0.1949462890625
▁Opt 6.9296875
im 0.40966796875
izing 1.2041015625
▁E 2.349609375
ffic 0.0007009506225585938
acy 0.0235137939453125
: 0.0517578125
<0x0A> 0.0030994415283203125
Wh 2.533203125
ile 0.00036334991455078125
▁Mar 1.265625
im 0.00022518634796142578
ast 2.014636993408203e-05
at 4.7087669372558594e-05
▁has 0.369384765625
▁shown 0.455078125
▁promise 1.318359375
▁in 0.0745849609375
▁pre 1.7080078125
cl 0.485595703125
in 1.9073486328125e-05
ical 1.8358230590820312e-05
▁and 0.60009765625
▁early 0.2161865234375
▁clin 0.66845703125
ical 2.205371856689453e-05
▁tri 0.2393798828125
als 4.172325134277344e-06
, 0.00323486328125
▁its 2.55078125
▁true 2.72265625
▁effect 3.412109375
iveness 0.003002166748046875
▁remains 1.6201171875
▁to 0.640625
▁be 8.237361907958984e-05
▁seen 2.05859375
. 0.861328125
▁Ad 6.69921875
van 0.1143798828125
cing 0.1591796875
▁to 1.701171875
▁late 1.9638671875
- 0.00696563720703125
stage 0.016021728515625
▁clin 0.81103515625
ical 5.3882598876953125e-05
▁tri 0.0217132568359375
als 3.5762786865234375e-07
▁will 1.2470703125
▁provide 3.66796875
▁cru 2.345703125
cial 5.4836273193359375e-06
▁ins 1.1806640625
ights 2.2649765014648438e-06
▁and 3.365234375
▁a 4.38671875
▁clearer 1.2822265625
▁understanding 1.923828125
▁of 0.0012979507446289062
▁the 0.322021484375
▁drug 0.012664794921875
' 0.0008234977722167969
s 6.628036499023438e-05
▁overall 5.04296875
▁effic 0.7236328125
acy 1.2636184692382812e-05
▁and 0.61669921875
▁potential 2.583984375
▁side 1.4736328125
▁effects 0.0016689300537109375
. 0.04949951171875
▁British 0.8671875
▁Bi 0.001361846923828125
ote 3.2186508178710938e-06
ch 4.6133995056152344e-05
▁Pl 0.0035533905029296875
c 3.0517578125e-05
▁must 0.37255859375
▁ensure 2.521484375
▁these 6.3125
▁tri 0.114990234375
als 5.9604644775390625e-06
▁are 0.1492919921875
▁conducted 1.6025390625
▁met 5.76171875
icul 2.1696090698242188e-05
ously 3.349781036376953e-05
▁to 2.705078125
▁maxim 1.49609375
ize 0.0014667510986328125
▁Mar 2.01171875
im 0.0002808570861816406
ast 0.00012183189392089844
at 0.00025272369384765625
' 0.0009527206420898438
s 3.9458274841308594e-05
▁th 2.5546875
era 1.2040138244628906e-05
pe 1.430511474609375e-06
ut 1.0728836059570312e-06
ic 2.276897430419922e-05
▁benefits 1.736328125
▁and 0.70751953125
▁minim 0.5703125
ize 0.00021970272064208984
▁any 0.6630859375
▁ris 1.4091796875
ks 1.6570091247558594e-05
. 0.5458984375
<0x0A> 0.329833984375
Con 4.58984375
clusion 0.1802978515625
: 0.205810546875
<0x0A> 9.8203125
As 1.9404296875
▁British 0.806640625
▁Bi 0.001003265380859375
ote 1.1920928955078125e-05
ch 0.00031495094299316406
▁Pl 0.0028438568115234375
c 0.00010347366333007812
' 2.52734375
s 0.0003685951232910156
▁cancer 4.671875
▁drug 0.38330078125
▁Mar 1.595703125
im 0.0002961158752441406
ast 3.981590270996094e-05
at 6.580352783203125e-05
▁progress 2.478515625
es 0.0007863044738769531
▁in 4.6953125
▁its 0.75341796875
▁development 1.8525390625
, 0.78564453125
▁the 1.033203125
▁path 2.654296875
▁towards 2.794921875
▁block 0.48291015625
b 4.00543212890625e-05
uster 0.0016002655029296875
▁status 0.04248046875
▁faces 5.79296875
▁significant 0.7353515625
▁hur 1.513671875
d 4.76837158203125e-07
les 1.1205673217773438e-05
. 0.300048828125
▁N 5.75390625
avig 0.0029201507568359375
ating 0.00014102458953857422
▁the 1.818359375
▁complex 1.4111328125
▁web 7.234375
▁of 0.00026607513427734375
▁regul 0.01401519775390625
atory 0.0004267692565917969
▁requirements 1.51953125
, 0.08880615234375
▁compet 1.7373046875
ing 1.814453125
▁against 1.6728515625
▁established 0.07086181640625
▁players 0.1942138671875
, 0.09698486328125
▁se 1.826171875
cur 9.179115295410156e-06
ing 2.6226043701171875e-06
▁ade 1.53125
qu 3.814697265625e-06
ate 1.0728836059570312e-05
▁fund 0.291748046875
ing 8.940696716308594e-06
, 0.09088134765625
▁and 0.25927734375
▁optim 0.6962890625
izing 0.0008521080017089844
▁clin 0.98193359375
ical 3.790855407714844e-05
▁trial 0.7822265625
▁out 0.65478515625
comes 2.6226043701171875e-06
▁are 0.826171875
▁just 0.94140625
▁some 0.92724609375
▁of 0.002132415771484375
▁the 0.0005850791931152344
▁challeng 0.576171875
es 0.00017368793487548828
▁to 3.966796875
▁overcome 0.4150390625
. 0.068603515625
▁Nevertheless 2.68359375
, 5.9604644775390625e-05
▁the 0.87744140625
▁immense 5.83203125
▁potential 0.10015869140625
▁and 2.8359375
▁early 3.478515625
▁promise 1.0791015625
▁exhib 6.09375
ited 0.002635955810546875
▁by 0.002777099609375
▁Mar 0.217041015625
im 0.0005927085876464844
ast 3.7550926208496094e-05
at 5.1021575927734375e-05
▁offer 2.05859375
▁hope 0.775390625
▁to 5.453125
▁patients 1.791015625
▁and 0.56640625
▁the 0.90478515625
▁wider 2.484375
▁medical 1.5126953125
▁community 0.003978729248046875
. 0.58642578125
▁The 3.248046875
▁bi 2.451171875
ote 0.00443267822265625
ch 0.0222320556640625
▁industry 0.03277587890625
▁eager 0.94384765625
ly 1.71661376953125e-05
▁a 0.04986572265625
wa 7.152557373046875e-07
its 1.7881393432617188e-06
▁the 1.9716796875
▁next 1.224609375
▁steps 1.3701171875
, 3.43359375
▁as 1.4501953125
▁successful 7.91796875
▁navigation 4.4609375
▁through 2.458984375
▁these 0.150390625
▁hur 2.1640625
d 5.0067901611328125e-06
les 9.429454803466797e-05
▁could 0.269775390625
▁potentially 3.701171875
▁make 4.37890625
▁Mar 0.12445068359375
im 0.0004417896270751953
ast 8.594989776611328e-05
at 7.903575897216797e-05
▁a 0.09515380859375
▁game 0.87353515625
- 0.018157958984375
ch 0.00017368793487548828
anger 0.255615234375
▁in 0.058441162109375
▁cancer 1.3134765625
▁treatment 0.05133056640625
. 0.1219482421875
